Keay Nakae
Stock Analyst at Chardan Capital
(4.05)
# 508
Out of 5,241 analysts
263
Total ratings
40.3%
Success rate
16.63%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Buy | $30 | $22.98 | +30.55% | 4 | Apr 22, 2026 | |
| PRQR ProQR Therapeutics | Maintains: Buy | $4 | $1.59 | +151.57% | 17 | Apr 9, 2026 | |
| IBIO iBio, Inc. | Maintains: Buy | $5 | $1.47 | +240.14% | 8 | Apr 9, 2026 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $59.27 | +68.72% | 8 | Mar 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $425 | $286.98 | +48.09% | 16 | Mar 25, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $35 | $30.08 | +16.36% | 2 | Mar 18, 2026 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $4.96 | +182.26% | 24 | Mar 16, 2026 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $3.72 | +437.63% | 14 | Mar 12, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $12 → $14 | $3.70 | +278.38% | 20 | Mar 11, 2026 | |
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $17.29 | +119.78% | 16 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $15 | $10.18 | +47.35% | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $80 | $76.67 | +4.34% | 23 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $4.24 | +17.92% | 14 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 | $13.23 | +444.22% | 21 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $6.10 | +473.77% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $7.64 | -21.47% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.75 | +242.86% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.36 | +2,143.41% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $14.99 | -59.97% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $0.53 | +71,395.77% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $7.94 | +592.70% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $2.84 | +252.11% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $23.11 | +278.62% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.39 | +835.25% | 3 | Feb 9, 2021 |
Alto Neuroscience
Apr 22, 2026
Maintains: Buy
Price Target: $30
Current: $22.98
Upside: +30.55%
ProQR Therapeutics
Apr 9, 2026
Maintains: Buy
Price Target: $4
Current: $1.59
Upside: +151.57%
iBio, Inc.
Apr 9, 2026
Maintains: Buy
Price Target: $5
Current: $1.47
Upside: +240.14%
Monopar Therapeutics
Mar 30, 2026
Maintains: Buy
Price Target: $100
Current: $59.27
Upside: +68.72%
Alnylam Pharmaceuticals
Mar 25, 2026
Maintains: Buy
Price Target: $425
Current: $286.98
Upside: +48.09%
Stoke Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $35
Current: $30.08
Upside: +16.36%
Coya Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $14
Current: $4.96
Upside: +182.26%
Orchestra BioMed Holdings
Mar 12, 2026
Maintains: Buy
Price Target: $20
Current: $3.72
Upside: +437.63%
SAB Biotherapeutics
Mar 11, 2026
Maintains: Buy
Price Target: $12 → $14
Current: $3.70
Upside: +278.38%
Dyne Therapeutics
Mar 9, 2026
Maintains: Buy
Price Target: $38
Current: $17.29
Upside: +119.78%
Jan 29, 2026
Upgrades: Buy
Price Target: $7 → $15
Current: $10.18
Upside: +47.35%
Jan 7, 2026
Maintains: Buy
Price Target: $60 → $80
Current: $76.67
Upside: +4.34%
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.24
Upside: +17.92%
Nov 11, 2025
Maintains: Neutral
Price Target: $72
Current: $13.23
Upside: +444.22%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $6.10
Upside: +473.77%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $7.64
Upside: -21.47%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $1.75
Upside: +242.86%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.36
Upside: +2,143.41%
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $14.99
Upside: -59.97%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $0.53
Upside: +71,395.77%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $7.94
Upside: +592.70%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $2.84
Upside: +252.11%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $23.11
Upside: +278.62%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.39
Upside: +835.25%